专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013156534A9 CROSS-REACTIVE STAPHYLOCOCCUS AUREUS ANTIBODY 审中-公开
公开(公告)号：WO2013156534A9
公开(公告)日：2013-10-24
申请号：PCT/EP2013/058022
申请日：2013-04-17
申请人： ARSANIS BIOSCIENCES GMBH
发明人： NAGY, Eszter , BADARAU, Adriana , ROUHA, Harald , STULIK, Lukas , NAGY, Gábor , MIRKINA, Irina , MAGYARICS, Zoltán , VISRAM, Zehra , JAEGERHOFER, Michaela , ZERBS, Manuel , DOLEZILKOVA, Ivana , TEUBENBACHER, Astrid , BATTLES, Michael Benjamin , PRINZ, Bianka Dominique
IPC分类号： C07K16/12 , A61K39/40 , A61P31/04
摘要： The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi- component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.

2. 发明申请

WO2016166221A1 ANTIBODY DIRECTED AGAINST IMMUNOGLOBULIN-BINDING PROTEINS OF S. AUREUS 审中-公开
标题翻译：针对S.Aureus的免疫抑制蛋白结合蛋白的抗体
公开(公告)号：WO2016166221A1
公开(公告)日：2016-10-20
申请号：PCT/EP2016/058238
申请日：2016-04-14
申请人： ARSANIS BIOSCIENCES GMBH
发明人： NAGY, Eszter , BADARAU, Adriana , ROUHA, Harald , STULIK, Lukas , MIRKINA, Irina , BATTLES, Michael B. , NIELSON, Nels
IPC分类号： C07K16/12 , C07K16/42
CPC分类号： C07K16/1271 , A61K39/40 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/01
摘要： A monoclonal antibody that counteracts Staphylococcus aureus by specifically binding to wild-type immunoglobulin-binding proteins (IGBP) of S. aureus comprising a cross-specific CDR binding site recognizing at least three of the IGBP domains selected from the group consisting of Protein A (SpA) domains and immunoglobulin-binding protein (Sbi) domains SpA-A, SpA-B, SpA-C, SpA-D, SpA-E, Sbi-I, and Sbi-ll, wherein the antibody has an affinity to bind SpA-E with a K D of less than 5x10 -9 M as determined by a standard optical interferometry method for a F(ab)2 fragment, and preferably binds to wt SpA equally or better compared to mutant SpA-KKAA that lacks binding to IgG Fc or VH3.
摘要翻译：通过与金黄色葡萄球菌的野生型免疫球蛋白结合蛋白（IGBP）特异性结合来抵抗金黄色葡萄球菌的单克隆抗体，其包含识别至少三种IGBP结构域的交叉特异性CDR结合位点，所述IGBP结构域选自蛋白A（ SpA）结构域和免疫球蛋白结合蛋白（Sbi）结构域SpA-A，SpA-B，SpA-C，SpA-D，SpA-E，Sbi-1和Sbi-11，其中抗体具有结合SpA -E，其通过用于F（ab）2片段的标准光学干涉测定方法测定的KD小于5×10 -9 M，并且优于与缺乏与IgG Fc结合的突变体SpA-KKAA相同或更好地与wt SpA结合， VH3。

3. 发明申请

WO2015091935A2 ANTIBODIES DIRECTED AGAINST THE LUKGH (LUKAB) TOXIN OF STAPHYLOCOCCUS AUREUS AND ANTIBODY SEQUENCES 审中-公开
标题翻译：针对罗非鱼（LUKAB）毒蕈碱和抗体序列的抗体
公开(公告)号：WO2015091935A2
公开(公告)日：2015-06-25
申请号：PCT/EP2014/078708
申请日：2014-12-19
申请人： ARSANIS BIOSCIENCES GMBH
发明人： NAGY, Eszter , BADARAU, Adriana , ROUHA, Harald , MIRKINA, Irina , BATTLES, Michael Benjamin , WALKER, Laura M , NIELSON, Nels , TUSHAR, S. Jain
IPC分类号： C07K16/12
CPC分类号： C07K16/1271 , A61K39/00 , C07K14/31 , C07K14/315 , C07K2317/21 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention provides for an antibody comprising at least one binding site that specifically binds to a LukGH complex, which antibody comprises at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Table 1, or functionally active CDR variants thereof.
摘要翻译：本发明提供了包含至少一个特异性结合LukGH复合物的结合位点的抗体，该抗体包含至少一个抗体重链可变区（VH），其包含表1所列的任何CDR1至CDR3序列，或其功能活性CDR变体。

4. 发明申请

WO2018029346A1 KLEBSIELLA PNEUMONIAE O3 SPECIFIC ANTIBODIES 审中-公开
标题翻译： KLEBSIELLA PNEUMONIAE O3特异性抗体
公开(公告)号：WO2018029346A1
公开(公告)日：2018-02-15
申请号：PCT/EP2017/070446
申请日：2017-08-11
申请人： ARSANIS BIOSCIENCES GMBH , MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E. V.
发明人： SZIJÁRTO, Valeria , NAGY, Gábor , GUACHALLA, Luis , HARTL, Katharina , BADARAU, Adriana , NAGY, Eszter , ROLLENSKE, Tim , WARDEMANN, Hedda , MIRKINA, Irina
IPC分类号： C07K16/12 , A61P31/00
摘要： A cross-neutralizing monoclonal antibody that specifically recognizes a cross- reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae , which is an O3b epitope, cross-reacting with an O3a epitope and an O3 5 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
摘要翻译：特异性识别克雷伯氏肺炎杆菌的脂多糖（LPS）抗原结构的交叉反应性表位的交叉中和单克隆抗体，其是与O3a表位和O3 5表位交叉反应的O3b表位，其中所述抗体以特异性CDR序列或VH和VL序列为特征。

5. 发明申请

WO2017064258A1 BACTERICIDAL MONOCLONAL ANTIBODY TARGETING KLEBSIELLA PNEUMONIAE 审中-公开
标题翻译：杀菌KLEBSIELLA PNEUMONIAE的杀菌单克隆抗体
公开(公告)号：WO2017064258A1
公开(公告)日：2017-04-20
申请号：PCT/EP2016/074728
申请日：2016-10-14
申请人： ARSANIS BIOSCIENCES GMBH
发明人： NAGY, Eszter , NAGY, Gábor , SZIJÁRTO, Valeria , GUACHALLA, Luis Miguel , MIRKINA, Irina , VISRAM, Zehra
IPC分类号： C07K16/12 , G01N33/50 , A61K39/395
CPC分类号： C07K16/1228 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/76 , G01N33/56916 , G01N2333/26
摘要： A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-ll antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.
摘要翻译：人特异性识别特征在于杀菌性CDC活性的肺炎克雷伯氏菌（Klebsiella pneumoniae）O1的D-半乳聚糖-II抗原的人或人源化单克隆IgG抗体（mAb），其方法生产，医疗和诊断用途。

6. 发明申请

WO2015055814A1 CROSS-REACTIVE STAPHYLOCOCCUS AUREUS ANTIBODY SEQUENCES 审中-公开
标题翻译：交叉反应性印迹黄连素抗体序列
公开(公告)号：WO2015055814A1
公开(公告)日：2015-04-23
申请号：PCT/EP2014/072316
申请日：2014-10-17
申请人： ARSANIS BIOSCIENCES GMBH
发明人： NAGY, Eszter , BADARAU, Adriana , ROUHA, Harald , NAGY, Gábor , MIRKINA, Irina , MAGYARICS, Zoltán , VISRAM, Zehra , BATTLES, Michael Benjamin , PRINZ, Bianka Dominique , JAIN, Tushar S.
IPC分类号： C07K16/12
CPC分类号： C07K16/1271 , C07K2317/33 , C07K2317/34 , C07K2317/515 , C07K2317/565 , G01N33/56938 , G01N2800/26
摘要： The invention refers to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi- component toxins of Staphylococcus aureus , which antibody comprises at least three complementarity determining regions (CDR1 to CDR3) of the antibody heavy chain variable region (VH), wherein A) the antibody comprises a) a CDR1 comprising or consisting of the amino acid sequence YSISSGMGWG (SEQ ID 1); and b) a CDR2 comprising or consisting of the amino acid sequence SIDQRGSTYYNPSLKS (SEQ ID 2); and c) a CDR3 comprising or consisting of the amino acid sequence ARDAGHGVDMDV (SEQ ID 3); or B) the antibody comprises at least one functionally active CDR variant of a) the parent CDR1 consisting of the amino acid sequence of SEQ ID 1; or b) the parent CDR2 consisting of the amino acid sequence of SEQ ID 2; or c) the parent CDR3 consisting of the amino acid sequence of SEQ ID 3; wherein the functionally active CDR variant comprises at least one point mutation in the parent CDR sequence, and comprises or consists of the amino acid sequence that has at least 60% sequence identity with the parent CDR sequence. It further refers to such cross-neutralizing antibody which is a functionally active variant antibody of a parent antibody that comprises a polyspecific binding site of the VH amino acid sequence of SEQ ID 20, and the VL amino acid sequence of SEQ ID 39, which functionally active variant antibody comprises at least one point mutation in any of the framework regions (FR) or constant domains, or complementarity determining regions (CDR1 to CDR6) in any of SEQ ID 20 or SEQ 39, and has an affinity to bind each of the toxins with a Kd of less than 10 -8 M, preferably less than 10 -9 M.
摘要翻译：本发明涉及包含至少一个与α-毒素（Hla）结合的多特异性结合位点和至少一种金黄色葡萄球菌的双组分毒素的交叉中和抗体，该抗体包含至少三个互补决定区（CDR1 抗体重链可变区（VH）的CDR3），其中A）抗体包含a）包含氨基酸序列YSISSGMGWG（SEQ ID 1）或由其组成的CDR1; 和b）包含或由氨基酸序列SIDQRGSTYYNPSLKS（SEQ ID 2）组成的CDR2; 和c）包含或由氨基酸序列ARDAGHGVDMDV（SEQ ID 3）组成的CDR3; 或B）抗体包含a）由SEQ ID No.1的氨基酸序列组成的亲本CDR1的至少一种功能活性CDR变体; 或b）由SEQ ID No.2的氨基酸序列组成的亲本CDR2; 或c）由SEQ ID 3的氨基酸序列组成的亲本CDR3; 其中所述功能活性CDR变体在所述亲本CDR序列中包含至少一个点突变，并且包含与所述亲本CDR序列具有至少60％序列同一性的氨基酸序列或由所述氨基酸序列组成。它还涉及这样的交叉中和抗体，其是包含SEQ ID 20的VH氨基酸序列的多特异性结合位点和SEQ ID 39的VL氨基酸序列的亲本抗体的功能活性变体抗体，其功能上是活性变体抗体包含SEQ ID NO：20或SEQ ID NO：39中任一个的框架区（FR）或恒定结构域或互补决定区（CDR1至CDR6）中的任一者的至少一个点突变，并具有与 Kd小于10-8M，优选小于10-9M的毒素。

7. 发明申请

WO2014111516A1 MDR E. COLI SPECIFIC ANTIBODY 审中-公开
标题翻译： MDR大肠杆菌特异性抗体
公开(公告)号：WO2014111516A1
公开(公告)日：2014-07-24
申请号：PCT/EP2014/050895
申请日：2014-01-17
申请人： ARSANIS BIOSCIENCES GMBH
发明人： NAGY, Eszter , NAGY, Gábor , SZIJÁRTO, Valéria , MAGYARICS, Zoltán , MIRKINA, Irina , GUACHALLA, Luis , BADARAU, Adriana , ZAUNER, Gerhild , LUKASIEWICZ, Jolanta
IPC分类号： A61K39/395 , A61P31/04 , C07K16/12
CPC分类号： A61K39/0258 , A61K2039/505 , A61K2039/55505 , A61K2039/55511 , A61K2039/55561 , C07K16/1232 , C07K2317/33 , C07K2317/73 , C07K2317/92 , G01N33/56916 , G01N2333/245 , G01N2469/10
摘要： The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
摘要翻译：该主题涉及特异性结合多药耐药（MDR）大肠杆菌菌株的O25b抗原的分离抗体，其医学和诊断用途，产生抗体的方法，包括分离的核苷酸序列，质粒和宿主细胞，如生产抗体; 并且进一步分离的表位识别特异性抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式